202. Smith-Magenis syndrome Disease details / Clinical trials / Drug dev / DR info

Clinical trials : 9 /  Drugs : 8 - (DrugBank : 3) / Drug target genes : 3 - Drug target pathways : 4

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)
Acylated and unacylated ghrelin dosages
   University Hospital, Toulouse
      2021   -   NCT04768803   France
Enviro-light artificial light BOX
   Oregon Health and Science University
      1998   -   NCT00691574   United States
Hourly dosing OF THE nychtemeral secretion OF melatonin
   Hôpital le Vinatier
      2018   -   NCT03492970   France
Melatonin
   Oregon Health and Science University
      1998   -   NCT00691574   United States
Melatonin CR
   National Human Genome Research Institute (NHGRI)
      2007   Phase 1   NCT00506259   United States
RM-493
   Rhythm Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2017-000387-14-GR   Canada;France;Germany;Greece;Israel;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-000387-14-GB   Canada;France;Germany;Greece;Israel;Netherlands;Spain;United Kingdom;United States
      -   Phase 2   EUCTR2017-000387-14-FR   Australia;Canada;France;Germany;Greece;Ireland;Israel;Netherlands;Portugal;Spain;Turkey;United Kingdom;United States
Setmelanotide
   Rhythm Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2017-000387-14-GR   Canada;France;Germany;Greece;Israel;Netherlands;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-000387-14-GB   Canada;France;Germany;Greece;Israel;Netherlands;Spain;United Kingdom;United States
      -   Phase 2   EUCTR2017-000387-14-FR   Australia;Canada;France;Germany;Greece;Ireland;Israel;Netherlands;Portugal;Spain;Turkey;United Kingdom;United States
Tasimelteon
   Vanda Pharmaceuticals
      2016   Phase 1   NCT02776215   United States
      2015   Phase 2/Phase 3   NCT02231008   United States